GAL and mood disorder: In conclusion, the demonstrated efficacy of intranasal GAL (1–15), combined with its favorable safety profile, positions GAL (1–15) as a promising candidate for advancing into more extensive clinical trials, allowing for a deeper understanding of its efficacy and long-term effects in therapeutic applications in treating mood disorders in combination with iSRS and substance use disorders.